Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial

Br J Psychiatry. 2005 Nov:187:450-5. doi: 10.1192/bjp.187.5.450.

Abstract

Background: Reality orientation therapy combined with cholinesterase inhibitors has not been evaluated in patients with Alzheimer's disease.

Aims: To perform such an evaluation.

Method: We randomly assigned 79 of 156 patients treated with donepezil to receive a reality orientation programme. Caregivers of the treatment group were trained to offer the programme at home 3 days a week, 30 min/day, for 25 consecutive weeks, and were invited to stimulate and involve patients in reality-based communication.

Results: The treatment group showed a slight improvement in Mini-Mental State Examination (MMSE) scores (mean change +0.2, s.e.=0.4) compared with a decline in the control group (mean change -1.1, s.e.=0.4; P=0.02). Similarly for the Alzheimer's Disease Assessment Scale--Cognition (treatment group mean change +0.4, s.e.=0.8; control group -2.5, s.e.=0.8; P=0.01). The intervention had an equal effect on cognition in those with mild (MMSE score > or = 20) and moderate (score <20) dementia. No significant effect was observed for behavioural and functional outcomes.

Conclusions: Reality orientation enhances the effects of donepezil on cognition in Alzheimer's disease.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / therapy*
  • Caregivers / education
  • Caregivers / psychology
  • Cholinesterase Inhibitors / therapeutic use*
  • Cognition
  • Combined Modality Therapy
  • Donepezil
  • Female
  • Humans
  • Indans / therapeutic use*
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Piperidines / therapeutic use*
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Reality Therapy* / education
  • Treatment Outcome

Substances

  • Cholinesterase Inhibitors
  • Indans
  • Piperidines
  • Donepezil